Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells

The Lancet Haematology

Volumn 2, Issue 5, 2015, Pages e204-e211

  Rushworth, Stuart A ^a   Pillinger, Genevra ^a   Abdul Aziz, Amina ^a   Piddock, Rachel ^a   Shafat, Manar S ^a   Murray, Megan Y ^a   Zaitseva, Lyubov ^a   Lawes, Matthew J ^c   MacEwan, David J ^b   Bowles, Kristian M ^a,c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; IBRUTINIB; INTEGRIN; STEM CELL FACTOR RECEPTOR; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW STROMA CELL; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MIDDLE AGED; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VERY ELDERLY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CYTOLOGY; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; MONONUCLEAR CELL; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 85014930845     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00046-0     Document Type: Article

References (44)

1. Welch, JS, Ley, TJ, Link, DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150 (2012), 264–278.
2. Kvinlaug, BT, Chan, WI, Bullinger, L, et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 71 (2011), 4117–4129.
3. Rushworth, SA, Macewan, DJ, Bowles, KM, Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 1278–1279.
4. Honda, F, Kano, H, Kanegane, H, et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 13 (2012), 369–378.
5. Horwood, NJ, Page, TH, McDaid, JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 176 (2006), 3635–3641.
6. Rushworth, SA, Bowles, KM, Barrera, LN, Murray, MY, Zaitseva, L, MacEwan, DJ, BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 25 (2013), 106–112.
7. Burger, JA, Buggy, JJ, Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54 (2013), 2385–2391.
8. Advani, RH, Buggy, JJ, Sharman, JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31 (2013), 88–94.
9. Tai, Y-T, Chang, BY, Kong, S-Y, et al. Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120 (2012), 1877–1887.
10. Kim, E, Koehrer, S, Rosin, NY, et al. Activity of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL). ASH Ann Meet Abstr, 120, 2012, 2569 (abstr).
11. Sivina, M, Kreitman, RJ, Arons, E, Buggy, JJ, Ravandi, F, Burger, JA, Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) blocks hairy cell leukemia (HCL) survival, proliferation, and BCR signaling: a new therapeutic approach for HCL. ASH Ann Meet Abstr, 120, 2012, 1802 (abstr).
12. Dasmahapatra, G, Patel, H, Dent, P, Fisher, RI, Friedberg, J, Grant, S, The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161 (2013), 43–56.
13. Wang, ML, Rule, S, Martin, P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369 (2013), 507–516.
14. Byrd, JC, Furman, RR, Coutre, SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 32–42.
15. Tomasson, MH, Xiang, Z, Walgren, R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111 (2008), 4797–4808.
16. Gu, T-l, Nardone, J, Wang, Y, et al. Survey of Activated FLT3 Signaling in Leukemia. PLoS One, 6, 2011, e19169.
17. Rushworth, SA, Murray, MY, Zaitseva, L, Bowles, KM, MacEwan, DJ, Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123 (2014), 1229–1238.
18. Ikeda, H, Kanakura, Y, Tamaki, T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78 (1991), 2962–2968.
19. Wang, C, Curtis, JE, Geissler, EN, McCulloch, EA, Minden, MD, The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3 (1989), 699–702.
20. Döhner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115 (2010), 453–474.
21. Bendall, LJ, Makrynikola, V, Hutchinson, A, Bianchi, AC, Bradstock, KF, Gottlieb, DJ, Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia, 12, 1998, 1375.
22. Matsunaga, T, Takemoto, N, Sato, T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 (2003), 1158–1165.
23. Ito, T, Smrž, D, Jung, M-Y, et al. Stem cell factor programs the mast cell activation phenotype. J Immunol 188 (2012), 5428–5437.
24. Koketsu, R, Suzukawa, M, Kawakami, A, et al. Activation of basophils by stem cell factor: comparison with insulin-like growth factor-I. J Investig Allergol Clin Immunol 18 (2008), 293–299.
25. Schmidt, U, van den Akker, E, Parren-van Amelsvoort, M, et al. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med 199 (2004), 785–795.
26. Rushworth, SA, Zaitseva, L, Langa, S, Bowles, KM, MacEwan, DJ, FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 1 (2011), 359–366.
27. Rushworth, SA, MacEwan, DJ, HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 111 (2008), 3793–3801.
28. Dohner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115 (2010), 453–474.
29. Juliusson, G, Antunovic, P, Derolf, A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113 (2009), 4179–4187.
30. Burnett, AK, Ham-Wasserman lecture. https://ash.confex.com/ash/2012/webprogram/Session3976.html Dec 8, 2012 (accessed March 1, 2013).
31. de Weers, M, Verschuren, MCM, Kraakman, MEM, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 23 (1993), 3109–3114.
32. Fiedler, K, Sindrilaru, A, Terszowski, G, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 117 (2011), 1329–1339.
33. Fiedler, K, Kokai, E, Bresch, S, Brunner, C, MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. Am J Blood Res 3 (2013), 124–140.
34. Meng, F, Francis, H, Glaser, S, et al. Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology 55 (2012), 209–221.
35. Chung, IJ, Dai, CH, Krantz, SB, Stem cell factor increases the expression of flip that inhibits ifn gamma-induced apoptosis in human erythroid progenitor cells. Blood 101 (2003), 1324–1328.
36. Ma, P, Vemula, S, Munugalavadla, V, et al. Balanced interactions between Lyn, the p85alpha regulatory subunit of class I(A) phosphatidylinositol-3-kinase, and SHIP are essential for mast cell growth and maturation. Mol Cell Biol 31 (2011), 4052–4062.
37. Sun, J, Pedersen, M, Ronnstrand, L, The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J Biol Chem 284 (2009), 11039–11047.
38. Miettinen, M, Lasota, J, KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13 (2005), 205–220.
39. de Rooij, MFM, Kuil, A, Geest, CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119 (2012), 2590–2594.
40. Gao, W, Wang, M, Wang, L, et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst, 106, 2014, dju204.
41. Dubovsky, JA, Beckwith, KA, Natarajan, G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122 (2013), 2539–2549.
42. Oellerich, T, Mohr, S, Corso, J, et al. FLT3-ITD and TLR9 employ Bruton's tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. Blood, 2015, 10.1182/blood-2014-06-585216 published online Jan 20.
43. Dos Santos, C, Demur, C, Bardet, V, Prade-Houdellier, N, Payrastre, B, Récher, C, A critical role for Lyn in acute myeloid leukemia. Blood 111 (2008), 2269–2279.
44. Hahn, CK, Berchuck, JE, Ross, KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16 (2009), 281–294.